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How extracellular signals communicate with the cell cycle is poorly understood. In this 
issue, two papers (Grimmler et al., 2007; Chu et al., 2007) address this problem by reporting 
phosphorylation of the cyclin-dependent kinase inhibitor p27Kip1 on a tyrosine residue by 
nonreceptor tyrosine kinases, which decreases p27 stability. This new mechanism could 
explain how cells enter the cell cycle from a quiescent state.The activities of cyclin-dependent kinase (Cdk) com-
plexes are thought to promote the transitions between 
cell-cycle phases by phosphorylating a plethora of sub-
strates. Cdk activity is controlled by multiple mecha-
nisms that include cyclin binding, phosphorylation, 
dephosphorylation, localization, transcriptional regula-
tion, protein degradation, and binding to inhibitors. One 
such inhibitor is p27Kip1, a member of the Cip/Kip family 
of Cdk inhibitors (Sherr and Roberts, 1999), which binds 
to Cdk2 (and to other Cdks) and potently inhibits Cdk2 
kinase activity. Therefore, p27 overexpression in human 
cells leads to cell-cycle arrest in the G1 phase. In quies-
cent cells (G0 phase), p27 levels are high concomitant 
with low Cdk activity. As cells enter the cell cycle and 
S phase, p27 levels decrease and the kinase activity 
of Cdks increases. p27 is a short-lived protein, and its 
degradation is controlled by the ubiquitin-proteasome 
system (Pagano et al., 1995). Cdk2 (or Cdk1) phospho-
rylates p27 at threonine 187, which is then recognized 
by the SCFSkp2 ubiquitin ligase and degraded by the 
proteasome (reviewed in Bloom and Pagano, 2003). In 
addition, there is a different ubiquitin ligase, KPC, which 
recognizes unphosphorylated p27 during G1 (Kamura et 
al., 2004). In this issue of Cell, two papers (Chu et al., 
2007; Grimmler et al., 2007) describe a new mechanism 
of p27 phosphorylation.
In vivo, mice lacking p27 are viable but are bigger than 
wild-type littermates. p27-deficient mice develop pituitary 
tumors and in some incidents retinal dysplasia, thymic 
hyperplasia, female sterility, and hyperplasia of the adrenal 
gland (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama 
et al., 1996). Therefore, p27 is not an essential gene but is 
important for growth control in vivo. The cell-cycle kinet-
ics of mouse embryonic fibroblasts lacking p27 is com-
parable to wild-type counterparts, but their Cdk2 activity 
is massively elevated. Given that p27 does not seem to 
inhibit Cdk4 or Cdk6 (Sherr and Roberts, 1999), most if 
not all phenotypes of p27-deficient mice were thought to 
be dependent on increased Cdk2 activity. However, Cdk2 
deletion in p27-deficient mice did not rescue p27-deficient 
phenotypes and lead to the discovery that Cdk1 is an in 
vivo target for p27 (Aleem et al., 2005).Based on these studies, a cell-cycle model was pro-
posed where Cdk activity, which promotes cell-cycle 
progression, is inhibited by p27, thereby causing cells 
to arrest. Nevertheless, there are a number of observa-
tions that do not fit this model. For example, overex-
pression of p27 in mouse embryonic fibroblasts and a 
few human cell lines does not result in complete G1 
arrest. In addition, low levels of p27 observed in human 
tumors do not correlate with the proliferation index 
(Loda et al., 1997). Thus, additional functions of p27 
may still be uncovered.
Entry into the cell cycle from quiescence is a major 
decision for cells. In order to activate Cdk/cyclin com-
plexes—which seems essential for cell-cycle entry—
inactive Cdk/cyclin/p27 complexes need to be converted 
into active complexes. Several mechanisms (such as 
transcription and degradation of cyclins, phosphoryla-
tion of Cdks, and inhibitors like p27) inhibit Cdk acti-
vation in G0. With respect to p27, re-entry into the cell 
cycle involves phosphorylation on threonine 187, which 
induces its degradation. Given that there is no detect-
able Cdk1 (or Cdk2, 3, 4, or 6) activity in G0, it is hard 
to imagine how p27 can be phosphorylated unless p27 
is phosphorylated by other kinases. Possibly a single 
(perhaps newly synthesized) active Cdk/cyclin complex 
could start an avalanche-like process in which every 
single p27 molecule removed from Cdk/cyclin com-
plexes would result in increased Cdk activity and there-
fore increased phosphorylation of p27. Although such a 
process cannot be excluded, it is unlikely to be the only 
mechanism.
Tyrosine Phosphorylation of p27 Initiates Its 
Degradation
Several groups now describe the phosphorylation of 
p27 on tyrosine residues (Chu et al., 2007; Grimmler et 
al., 2007; Kardinal et al., 2006). Grimmler et al. (2007) 
find that the nonreceptor tyrosine kinase Lyn binds to 
p27 and phosphorylates it on tyrosine 88 when both 
proteins are overexpressed in cell lines. The nonre-
ceptor tyrosine kinase Abl also phosphorylates p27 
on tyrosine 88 and to a lesser extent on tyrosine 89. Cell 128, January 26, 2007 ©2007 Elsevier Inc. 241
Although tyrosine phosphorylation of p27 reduced its 
ability to inhibit Cdk2 by approximately 10-fold, this 
version of p27 is still able to bind Cdk2/cyclin A com-
plexes through interactions with cyclin A and Cdk2. 
NMR analysis indicated that the 310-helix of p27 did 
not make contact with Cdk2 when p27 was phosphor-
ylated on tyrosine (Figure 1). The 310-helix of p27 con-
tains tyrosine 88, which is normally inserted into the 
ATP binding site of Cdk2 preventing catalytic activity 
(Russo et al., 1996). Therefore, tyrosine-phospho-
rylated p27 cannot effectively inhibit Cdk2 activity. 
Grimmler et al. (2007) also detected increased threo-
nine 187 phosphorylation of tyrosine-phosphorylated 
p27 leading to decreased p27 protein levels presum-
ably through increased ubiquitylation. Mutant p27Y88F, 
which cannot be phosphorylated on tyrosine 88, dis-
played increased stability in cells, probably because 
phosphorylation of threonine 187 and subsequent 
degradation would be less efficient.
Chu et al. (2007) investigated primary human breast 
cancers and found a loose correlation between low 
levels of p27 and activated Src kinase. In vitro, Src—
but not inactivated Src—phosphorylated p27 on tyro-
sine 74 and 88, which leads to decreased binding to 
Cdk2. Therefore, tyrosine-phosphorylated p27 is not 
an efficient inhibitor of Cdk2 activity in comparison to 
wild-type p27. Inhibition of Src by the phosphatase 
PP1 or small interfering RNA decreased tyrosine 
phosphorylation and increased protein stability of 
p27, which was correlated with decreased phospho-
rylation of threonine 187.
Kardinal et al. (2006) found in human acute pro-
myelotic leukemia NB4 cells that p27 interacts with 
the G-CSF receptor and Grb2 when p27 was tyro-
sine-phosphorylated. Treatment with G-CSF leads to 
decreased p27 tyrosine phosphorylation and dimin-
ished interaction with Cdk4, although Cdk2 binding 
was not affected. Phosphorylation of 
p27 by Abl increased p27’s affinity for 
Cdk4 while decreasing it for Cdk2.
All three papers indicate that p27 is 
phosphorylated on tyrosine, resulting 
in decreased p27 protein stability. The 
tyrosine residue differs (tyrosine 88 
and to some extent 74, 89), but the overall effect seems 
similar. The interesting aspect is the connection of tyro-
sine kinases (extracellular signals) to cell-cycle regula-
tion. Such a connection has been thought to exist, but 
the molecular mechanism had not been determined. 
The papers discussed here provide evidence for such a 
mechanism, and this feature should be incorporated in 
future cell-cycle models. However, these results have to 
be treated with caution because they were obtained by 
overexpressing p27 and tyrosine kinases in cell lines and 
it is unknown whether p27 is tyrosine-phosphorylated 
in vivo.
In terms of biochemistry and structural biology of 
Cdk/cyclin/p27 complexes, tyrosine phosphorylation of 
p27 adds a new dimension. As mentioned, when cells 
enter the cell cycle, inactive Cdk2/cyclin/p27 complexes 
have to be converted into active complexes. To achieve 
this goal there are three possibilities: (1) to degrade p27 
through ubiquitin-mediated proteolysis resulting in acti-
vation of Cdk2/cyclin complexes, (2) to synthesize new 
Cdk2 and cyclin molecules without increasing p27 lev-
els, or (3) to propose transient binding of p27 to Cdk 
complexes through interactions with the cyclin subunit 
without inhibiting Cdk activity. The first possibility is 
straightforward but does not explain how p27 can be 
phosphorylated when bound to Cdk2/cyclin complexes, 
as there is no measurable Cdk1, 2, 3, 4, and 6 kinase 
activity available in G0. Tyrosine phosphorylation of p27 
by tyrosine kinases provides a mechanism on how to 
reactivate Cdk2/cyclin complexes when p27 is bound. 
As mentioned above, tyrosine-phosphorylated p27 
remains bound to Cdk2/cyclin complexes, but p27 does 
not obstruct the ATP binding site of Cdk2, thereby allow-
ing efficient phosphorylation of p27 on threonine 187 by 
Cdk2 and subsequent p27 degradation (Figure 1). The 
second possibility is difficult to prove experimentally. 
Newly synthesized Cdk2 or cyclins cannot be isolated 
Figure 1. p27Kip1 Binding to Cdk/cyclin 
Complexes
p27 inhibits cyclin-dependent kinase (Cdk) ac-
tivity. Phosphorylation of p27 by Cdk2 and Cdk1 
leads to the ubiquitylation (by ubiquitin ligases 
such as Skp2) and degradation of p27. Grim-
mler et al. (2007) and Chu et al. (2007) describe 
tyrosine phosphorylation of p27 by nonreceptor 
tyrosine kinases, followed by phosphorylation 
of p27 on threonine 187 and p27 degradation. 
Interestingly, p27 phosphorylation by tyrosine 
kinases results in “active” Cdk complexes that 
are still bound to p27. Phosphorylation of p27 by 
tyrosine kinases is a way for extracellular signals 
to feed into the cell cycle.242 Cell 128, January 26, 2007 ©2007 Elsevier Inc.
and separated from existing Cdk2/cyclin/p27 com-
plexes. Perhaps new methods will be developed in the 
future to address such questions. The third possibility 
has been suggested by using mutants of p27 that can 
only interact with cyclins or only Cdks but not with both 
(Vlach et al., 1997). Nevertheless, it is conceivable that 
all possibilities occur simultaneously in vivo.
Unsolved Pieces of the Puzzle
As with all good scientific reports, the current ones 
raise more new questions than they answer. Among 
the top issues regarding p27 is the difference between 
Cdk2 and Cdk4 (or Cdk6). In vivo, the majority of p27 
molecules are bound to Cdk4, and only a small pro-
portion of p27 is bound to Cdk2 (there is no free p27 
detectable in vivo). Therefore, Cdk4 is a sink for p27 
molecules and could be an assembly factor for Cdk4/
cyclin D complexes (LaBaer et al., 1997). In the past, 
it has been accepted that p27 is a potent inhibitor of 
Cdk2. This has been based on the inability to observe 
Cdk2/cyclin/p27 complexes with measurable kinase 
activity. The current reports challenge this notion by 
demonstrating that p27 can bind to Cdk2 without 
inhibiting its activity. In contrast, active Cdk4/cyclin 
D/p27 complexes have been reported (Blain et al., 
1997; Soos et al., 1996). Based on these observa-
tions, tyrosine phosphorylation of p27 would provide 
an ideal explanation, if tyrosine-phosphorylated p27 
would inhibit Cdk2 but not Cdk4, or if tyrosine-phos-
phorylated p27 would preferentially bind to Cdk4. 
Given that Grimmler et al. (2007) and Chu et al. (2007) 
mostly investigate Cdk2, we can only speculate how 
tyrosine-phosphorylated p27 is interacting with Cdk4. 
Based on these two papers, there is no indication that 
tyrosine-phosphorylated p27 interacts differently with 
Cdk2 than Cdk4. Kardinal et al. (2006) suggest dif-
ferential interaction of Cdk2 and Cdk4 with GST-p27. 
It would be interesting to know whether expression 
of p27Y88F does affect the assembly of Cdk4/cyclin D 
complexes in vivo. Most likely, we have to await further 
experiments to address the relation of tyrosine-phos-
phorylated p27 and Cdk4.
Another interesting aspect of these findings deals 
with the interaction of tyrosine 88 in p27 and the ATP 
binding site of Cdk2 (Figure 1). The crystal structure of 
Cdk2/cyclin A/p27 complexes indicated that tyrosine 
88 is buried inside the ATP binding pocket of Cdk2 
(Russo et al., 1996). Based on this, it is hard to imag-
ine how tyrosine kinases are able to phosphorylate 
tyrosine 88. Nevertheless, Grimmler et al. (2007) dem-
onstrate that this is possible albeit less efficient than 
phosphorylation of free p27. In this regard, it would be 
interesting to know which percentage of the total p27 
molecules are tyrosine-phosphorylated during the 
cell-cycle phases. Furthermore, tyrosine-phospho-
rylated p27 is bound to Cdk2 without inserting into 
the ATP binding site. This would imply that Cdk2/cyc-
lin/tyrosine-phosphorylated p27 complexes can dis-play comparable activity as Cdk2/cyclin complexes. 
It should be feasible to determine the binding kinetics 
of ATP and substrate specificity of these complexes 
in the future.
Tyrosine phosphorylation leads to increased phos-
phorylation on threonine 187 and decreased stability of 
p27. This implies that tyrosine-phosphorylated p27 is 
more efficiently ubiquitylated by SCFSkp2. This assump-
tion should be confirmed experimentally because, for 
example, a knockin of mutant p27T187A displayed only a 
mild phenotype in mice (Malek et al., 2001), although 
colon adenomas in these animals were less likely to 
progress to carcinomas (Timmerbeul et al., 2006). A 
final issue to be resolved is the timing of p27 phos-
phorylation on tyrosine and its degradation. Although, 
the former is assumed to occur minutes after a qui-
escent population is exposed to mitogens, the latter 
occurs hours later. Thus, it is not unlikely that there 
are additional pathways controlling p27 stability (like 
the ubiquitin ligase KPC).
Phosphorylation of p27 has been studied extensively 
and the following phosphorylation sites have been 
described: serine 10; threonine 157 (not conserved in 
mouse p27), 187, and 198; and now tyrosine 74, 88, 
and 89 (Figure S1). These phosphorylation events 
might impinge on the biological functions of p27. For 
each of the phosphorylation sites, several kinases 
have been reported and different (at times contradict-
ing) functions have been ascribed. In these studies, 
there is a common thread leading back to serine 10, 
which is the major p27 phosphorylation site. Actu-
ally, it is estimated that 75% of phosphate incorpora-
tion occurs at serine 10, even when activated Lyn is 
coexpressed (Grimmler et al., 2007). The importance 
of serine 10 phosphorylation is corroborated in vivo, 
since p27S10A is resistant to Ras-induced translocation 
into the cytoplasm and p27S10A knockin mice are less 
tumor prone (Besson et al., 2006). In addition, there 
have been confusing reports concerning the kinases 
phosphorylating specific residues. In some cases this 
can be traced back to the source of the recombinant 
kinase as, for example, it has been shown that Akt from 
three commercial sources display different substrate 
specificities (Nacusi and Sheaff, 2006). Similarly, it is 
unclear why coexpression of Lyn and p27Y88F leads to 
increased threonine 187 phosphorylation (Grimmler et 
al., 2007) unless Lyn harbors functions that are inde-
pendent of tyrosine 88.
Tyrosine-Phosphorylated p27 In Vivo and Cancer
The novel finding of tyrosine-phosphorylated p27 is 
changing our view of p27/Cdk interactions, p27 deg-
radation, and control of the cell cycle by tyrosine 
kinases. We are left to wonder how tyrosine phos-
phorylation influences p27 functions in vivo. Chu et 
al. (2007) show that some human breast cancers are 
characterized by low p27 levels, which is associated 
with poor prognosis. One possibility to explain low p27 Cell 128, January 26, 2007 ©2007 Elsevier Inc. 243
levels in these cancers are the elevated levels of Cdk 
activity, which would in turn phosphorylate threonine 
187 in p27. This is the basic mechanism of a feedback 
loop. Now, Chu et al. (2007) provide a new explana-
tion. In a number of cancer samples, a correlation of 
low p27 with hyperactivated Src kinase was observed. 
Src would be able to phosphorylate p27 on tyrosine, 
which leads to decreased levels of p27. This appeal-
ing hypothesis might be tested by staining sections of 
cancers with phospho-tyrosine-p27 antibodies. Most 
likely though, this is one of many mechanisms that 
contribute to low p27 levels in cancer. Other means 
like the feedback loop (mentioned above) and altera-
tions in the ubiquitin pathway are likely to aid Src in 
keeping p27 levels low. For example, an inverse corre-
lation of Skp2 and p27 expression has been observed 
in tumors (reviewed in Bloom and Pagano, 2003). 
Therefore, staining of the same tumors for Skp2 would 
be informative.
The other interesting connection is BCR-ABL, an 
oncogene resulting from the Philadelphia translocation, 
which causes acute lymphoblastic and chronic myel-
ogenous leukemia. BCR-ABL is a hyperactive form of 
Abl and phosphorylates p27 on tyrosine. Grimmler et 
al. (2007) demonstrate that inhibition of BCR-ABL with 
STI-571 (Gleevec, Imatinib) increases p27 protein levels, 
which probably results in decreased cell proliferation. 
Based on this, it would be interesting to know whether 
the effectiveness of STI-571 to combat cancer is related 
to stabilization of p27 and whether this applies to all 
BCR-ABL positive cancers.
The puzzle of p27’s in vivo functions has not been 
solved yet, but based on the new observation of tyrosine 
phosphorylation in p27 along with many other advances 
in the p27 field, we expect a bright future. Therefore, 
manipulating p27 levels in cancer could hold one of the 
important keys for cancer therapy.
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